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ABSTRACT 
The goals of the Association for Molecular Pathology  Pharmacogenomics (PGx) Working Group of the 
Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles 
recommended for clinical testing and a minimum set of variants that should be included in clinical PGx 
genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and 
an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 
testing. The Working Group considered functional impact of the variants, allele frequencies in different 
populations and ethnicities, the availability of reference materials, as well as other technical considerations for 
PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx 
genes/allele testing across clinical laboratories. These recommendations are not to be interpreted as restrictive 
but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all 
CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include 
recommendations on CYP2C9 alleles and additional warfarin sensitivity–associated genes/alleles.  
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INTRODUCTION 
The Association for Molecular Pathology (AMP) Pharmacogenomics (PGx) Working Group describes a 
minimum list of alleles to include in clinical cytochrome P450 2C9 (CYP2C9) genotyping panels. These 
recommendations are developed to guide clinical laboratory professionals who validate and offer clinical PGx 
assays, with the goal of promoting standardization of PGx testing across different laboratories. This series of 
AMP PGx Working Group documents should be implemented with other clinical guidelines such as those issued 
by the Clinical Pharmacogenetics Implementation Consortium (CPIC), which focus primarily on the interpretation 
of genotyping results and therapeutic recommendations for a specific drug(s).
1
 The results of this study suggest 
variants for inclusion in clinical CYP2C9 genotyping panels and defines the key attributes of those alleles that 
were chosen for recommendation in clinical PGx testing.   
Clinical PGx testing assays across different laboratories differ with regard to both the star (*) allele 
haplotypes tested in each pharmacogene, as well as in the variants used to define those haplotypes.
2,3
 A Genetic 
Testing Reference Material Program (GeT-RM) study
4
 evaluated a number of PGx test panels across 28 genes in 
137 genomic DNA samples, and found discrepant results between mostly attributable to assay design. Without 
exception, no two tests that examined any of the 28 PGx genes included in the study were designed to detect 
the same set of variants and/or haplotypes (alleles). This genotyping variability can result in discrepancies in 
haplotype and diplotype assignment, which may affect test interpretation, and ultimately patient care. For 
example, if a patient’s genome harbors a heterozygous CYP2C9 NM_000771.3:c.449G>A, p.Arg150His; 
rs7900194 variant, which defines the *8 (reduced function) allele common among African-Americans and 
Africans,
5,6
 but the patient undergoes a test that does not include this variant, he or she may be assigned a 
genotype of *1/*1 (normal function) rather than *1/*8, impacting the predicted phenotype and clinical 
treatment strategy and potentially creating a health care disparity. Variability in the PGx alleles tested by 
different clinical laboratories has also led to discrepant results on proficiency testing (PT) surveys.3 
The AMP PGx Working Group was formed to derive a minimum set of alleles/variants that should be 
included in clinical PGx genotyping test panels, and to define the key attributes of the selection of these alleles.  
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This group has previously published recommendations for variants that should be included in any clinical 
CYP2C19 genotyping assay.
7
 Through that effort, the committee developed a “two-tier” strategy and selection 
criteria for recommended PGx clinical testing.  “Tier 1” recommended PGx variant alleles are those that i) have 
been well characterized and shown to significantly affect the function of the protein and/or gene leading to an 
alteration in a drug response phenotype, ii) have an appreciable minor allele frequency in a population/ethnicity 
group, and iii) have publicly available reference materials (RMs). Alleles/variants that currently meet at least one 
but not all three of the Tier 1 criteria are included as “Tier 2” variant alleles, which may be moved to Tier 1 if 
RMs or additional information becomes available. A description on the rationale for these clinical PGx testing 
recommendations and development of this two-tier classification strategy have been previously described in the 
CYP2C19 recommendation document from this group.
7
 
Gene: CYP2C9 
The cytochrome P450 2C9 is a member of the CYP2C subfamily of the cytochrome P450 enzymes, and is 
one of the most abundant and important drug metabolizing enzymes.  It has been estimated that ~15% of all 
CYP-related biotransformation is catalyzed by CYP2C9, including several widely prescribed medications with a 
narrow therapeutic index such as the anticoagulant warfarin and the anticonvulsant phenytoin.
8
 Like other CYP 
enzymes, CYP2C9 catalyzes a variety of exogenous and endogenous compounds, many of which are also 
substrates for other phase I and/or phase II enzymes. Medications for which CYP2C9 is responsible for >25% of 
metabolic clearance have been summarized elsewhere.
9
  
CYP2C9 is currently included in the Food and Drug Administration (FDA) Table of Pharmacogenetic 
Biomarkers in Drug Labeling for several FDA-approved drugs 
(https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm, last accessed 8/15/2018). The CYP2C9 gene has 
nine exons and is located on chromosome 10q23.33 where several CYP2C subfamily members (CYP2C18, 
CYP2C19, CYP2C9, and CYP2C8) are clustered. Like other CYP450 genes, CYP2C9 is highly polymorphic and 
variant CYP2C9 star (*) alleles are frequently included in clinical PGx testing assays. The two most well-
characterized variant alleles are CYP2C9*2 (NM_000771.3:c.430C>T, p.Arg144Cys, rs1799853) and CYP2C9*3 
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(NM_000771.3:c.1075A>C, p.Ile359Leu, rs1057910), both of which are associated with decreased enzyme 
activity and impaired drug metabolism phenotypes.
10
 Among the 60 variant CYP2C9 star (*) alleles listed on the 
PharmVar (The Pharmacogene Variation Consortium) website
11
 (formerly “the Human Cytochrome P450 (CYP) 
Allele Nomenclature website”), at least 20 are reported to have in vivo and/or in vitro functional evidence of 
altered activity (https://www.pharmvar.org/gene/CYP2C9, last accessed 8/15/2018). 
According to the Genetic Testing Registry, (https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=CYP2C9, 
last accessed 8/15/2018) and AMP Test Directory (https://www.amp.org/resources/test-directory/, last 
accessed 8/15/2018), the alleles included in CYP2C9 genotyping tests offered by clinical laboratories in the 
United States range from a few targeted alleles to interrogation of the entire coding region, and the techniques 
include targeted genotyping, bidirectional Sanger sequencing, next-generation sequencing (NGS), whole genome 
sequencing (WGS), or whole exome sequencing (WES), with or without deletion/duplication analysis. 
Inconsistent clinical results across laboratories12 may be attributed to the selection of tested CYP2C9 alleles, 
targeted testing of populations with varying ethnic backgrounds, as well as technical performance of the testing 
platforms. Differences can also occur post-analytically, during PGx interpretation and/or reporting; however, 
addressing these issues is considered outside the scope of this series of AMP PGx recommendation documents. 
Existing Guidelines 
Clinical PGx guidelines are available from groups including CPIC (https://cpicpgx.org, accessed 
8/15/2018), the Dutch Pharmacogenetics Working Group (DPWG) funded by the Royal Dutch Pharmacists 
Association
13
 and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) (http://cpnds.ubc.ca/, last 
accessed 8/15/2018). CPIC’s (and others) goals are to address barriers to clinical implementation of 
pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, 
updatable, and detailed gene/drug clinical practice guidelines (https://cpicpgx.org/).  These guidelines, which 
were developed using extensive literature review and discussion among experts, are gene-drug pair oriented 
with an emphasis on interpretation of genotype and phenotype, and genotype-guided therapeutic 
recommendations. These documents have played a critical role in shaping the clinical implementation of PGx 
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tests and have facilitated development of clinical decision support tools for clinicians to better understand and 
more efficiently utilize PGx testing results. There are currently 10 guidelines available on CYP2C9-metabolized 
medications from the CPIC, DPWG, and CPNDS (PharmGKB,
14
 
https://www.pharmgkb.org/gene/PA126/guideline, last accessed 8/15/2018). Although some clinical PGx 
guidelines include summaries of known CYP2C9 alleles, frequencies in various populations, and their functional 
and/or clinical relevance, they do not explicitly recommend specific variant alleles for clinical laboratories to 
include in CYP2C9 genotyping panels. Moreover, while the FDA recognizes the role of CYP2C9 genetic variability 
for a number of medications, very limited information is usually available in FDA product labels regarding the 
testing methods employed by drug manufacturers while conducting PGx studies. Despite the fact that many 
commercial platforms are available, clinical laboratories often develop their own laboratory tests for CYP2C9 
genotyping. Specific considerations from a diagnostic laboratory perspective such as allele selection, testing 
platforms, and availability of RMs have not been the focus of the consortia guidelines. However, consistency in 
clinical genotyping panels among clinical laboratories could further promote the utilization of these important 
clinical PGx practice guidelines.  
The AMP PGx Working Group reviewed the variant CYP2C9 star (*) alleles currently cataloged by 
PharmVar,
11
 including allele function, multiethnic allele frequencies, the availability of RMs, and commercially 
available genotyping platforms (Table 1). Tier 1 recommended CYP2C9 variant alleles were defined as those that 
have i) well-characterized alteration of CYP2C9 activity that has been shown to have an effect on drug 
response
15
 and for which the functional variant is known, ii) appreciable minor allele frequency in a population 
(https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx, last accessed 
8/15/2018), and iii) publicly available RMs (Table 2). Tier 2 CYP2C9 variant alleles are defined as alleles that meet 
at least one but not all of the criteria for inclusion in Tier 1, and are considered optional for inclusion in 
expanded clinical genotyping panels. Some of the Tier 2 alleles may be recommended as Tier 1 in the future if 
RMs or additional information becomes available. Variants with unknown or uncertain function are not 
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recommended for inclusion in targeted clinical CYP2C9 genotyping test panels, although it may be useful to 
include these in research panels to clarify functional and/or clinical outcomes.   
 
Tier 1 CYP2C9 Variant Alleles 
CYP2C9 variant alleles recommended as Tier 1 by the AMP PGx Working Group include CYP2C9 *2, *3, 
*5, *6, *8, and *11. This recommendation was based on their well-established functional effects on CYP2C9 
activity and drug response,
15
 availability of RMs, and their appreciable allele frequencies in major ethnic groups 
(https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx, last accessed 
8/15/2018). The CYP2C9*2 and *3 alleles are the most common CYP2C9 alleles interrogated by commercially 
available platforms (Table 1).  Importantly, the inclusion of these two variants accounts for 98% to 100% of the 
currently defined variation in CYP2C9 leading to decreased function in European, Middle Eastern, and Asian 
populations, but only ~25% of the currently defined CYP2C9 variation in populations with African ancestry (Table 
3). Thus, genotyping for only the CYP2C9*2 and *3 variants will not detect the majority of CYP2C9 genomic 
variation leading to decreased enzymatic activity in populations with African ancestry. The CYP2C9*5, *6, *8, 
and *11 alleles have a combined frequency of ~10% in populations with African ancestry and collectively are 
more common than the *2 and *3 alleles in these populations, accounting for ~75% of the currently defined 
CYP2C9 variation in African and African-Americans.  In contrast, these alleles have frequencies less than 0.4% in 
European and Asian populations 
(https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx, last accessed 
8/15/2018), accounting for <3% of currently defined CYP2C9 variation in those populations. 
 
CYP2C9*2 
The decreased function CYP2C9*2 allele is characterized by the presence of a missense variant in exon 3 
(NM_000771.3:c.430C>T, p.Arg144Cys, rs1799853) that causes a decrease in CYP2C9 enzymatic activity towards 
most of its substrates.
16–18
 CYP2C9*2 has an allele frequency ranging from 11% to 13% in European, Middle 
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Eastern, and South/Central Asian populations, but only ~2% in populations with African ancestry, and <1% in the 
East Asian population 
(https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx, last accessed 
8/13/2018).  This variant is also present in the CYP2C9*35 allele that is defined by the additional presence of an 
arginine to leucine change at amino acid 125 (NM_000771.3:c.374G>T, p.Arg125Leu, rs72558189)
19
 
(https://www.pharmvar.org/gene/CYP2C9, accessed 8/15/2018). The functional effect of the CYP2C9*35 
defining variant is yet unknown. 
 
CYP2C9*3 
The decreased function CYP2C9*3 allele has a missense variant in exon 7 (NM_000771.3:c.1075A>C, 
p.Ile359Leu, rs1057910) that causes significant reduction in enzymatic activity.
16,20
 The magnitude of enzyme 
impairment caused by CYP2C9*3 is more pronounced than that of CYP2C9*2 for most important drug 
substrates.
21
 Its frequency ranges from 7% to 10% in populations of European, Middle Eastern, and 
South/Central Asian ancestry, but is much lower in populations of African (~1%) and East Asian (~3%) ancestry 
(https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx, last accessed 
8/13/2018). The CYP2C9*3 defining variant (NM_000771.3:c.1075A>C, p.Ile359Leu, rs1057910) is also present in 
CYP2C9*18, which additionally harbors a missense variant (NM_000771.3:c.1190A>C, p.Asp397Ala, 
rs72558193). Very limited in vitro data are available on the functional effects of CYP2C9*18, which was initially 
identified in Indians.
22,23
  
 
CYP2C9*5 
The CYP2C9*5 allele, which has been found almost exclusively in subjects of African descent, is 
characterized by a missense variant in exon 7 (NM_000771.3:c.1080C>G, p.Asp360Glu,rs28371686) and is 
associated with reduced enzymatic activity.
23
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CYP2C9*6 
The CYP2C9*6 allele is defined by a single nucleotide deletion in exon 5 that causes a frameshift 
(NM_000771.3:c.818delA, p.Lys273Argfs, rs9332131).
24
 Although this allele has a lower frequency than the 
other decreased activity alleles among African-Americans and Africans (Table 3), its null activity and association 
with central nervous system phenytoin toxicity
24
 and reduced warfarin dose requirements
25
 makes it an 
important allele to interrogate when clinically genotyping CYP2C9. 
 
CYP2C9*8 
The CYP2C9*8 allele is defined by a missense variant in exon 3 (NM_000771.3:c.449G>A, p.Arg150His, 
rs7900194) and is the most frequent decreased function allele among African-Americans and Africans (Table 3). 
The c.449G>A variant is very rare in most other populations 
(http://gnomad.broadinstitute.org/dbsnp/rs7900194, last accessed 8/15/2018). Although this allele results in 
decreased enzymatic function towards warfarin and phenytoin, it has been reported to exhibit substrate-
specificity. For example, an in vitro study reported that it may confer increased enzymatic activity towards 
tolbutamide.
26
 However, two promoter variants, NM_000771.3:c.-1766T>C (rs9332094) and NM_000771.3:c.-
1188T>C (rs4918758), which are in strong linkage disequilibrium with the defining CYP2C9*8 variant (rs7900194) 
and have been associated with decreased CYP2C9 expression, may also contribute to the effects of the *8 
allele.
27
  Moreover, given the high homology in DNA sequence at the NM_000771.3:c.449G>A locus among 
CYP2C genes, genotyping for the NM_000771.3:c.-1766T>C polymorphism has been proposed as an alternative 
means of identifying CYP2C9*8.
28
 Substrate specificity may limit the classification of this allele as a decreased 
function allele when assigning a likely phenotype if used to inform medications other than phenytoin or warfarin 
(eg, sulfonylureas).6,29,30  Both in vivo and in vitro studies have shown that decreased warfarin clearance is 
associated with CYP2C9*8.31 Although its functional impact is less well-characterized than the *2 and *3 alleles, 
the *8 allele was chosen as Tier 1 allele due to its prevalence in populations of African descent, among whom 
warfarin has been widely used.  Due to concerns of substrate specificity for the CYP2C9*8 allele, clinicians 
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should be cautious when interpreting genotypic results and taking clinical action for any substrate other than 
those that have been extensively characterized.  Also of note, NM_000771.3:c. 449G>A/C/T is a tetraallelic 
variant also reported as NM_000771.3:c.449G>T, p.Arg150Leu, rs7900194 (CYP2C9*27) which should be taken 
into consideration when designing new assays or interpreting analytic results.   
 
CYP2C9*11 
The CYP2C9*11 allele is defined by a missense variant (NM_000771.3:c.1003C>T, p.Arg335Trp, 
rs28371685) in exon 7. This allele has been reported across all ethnicities and is also prevalent among African-
Americans and Africans (Table 3). Consistent with other Tier 1 recommended CYP2C9 alleles, CYP2C9*11 has 
been associated with impaired warfarin metabolism and lower dose requirements.
32
 
 
Tier 2 CYP2C9 Variant Alleles 
The following CYP2C9 alleles are recommended for inclusion in Tier 2: CYP2C9*12, *13, and *15 (Table 
4).  The CYP2C9*12 allele is defined by a missense variant in exon 9 (NM_000771.3:c.1465C>T, p.Pro489Ser, 
rs9332239); CYP2C9*13 is defined by a missense variant in exon 2 (NM_000771.3:c.269T>C, p.Leu90Pro, 
rs72558187); and CYP2C9*15 is defined by a nonsense variant in exon 4 (NM_000771.3:c.485C>A, p.Ser162*, 
rs72558190). These alleles have been shown to have either decreased function or no function 
(https://www.pharmvar.org/gene/CYP2C9, last accessed 8/15/2018) towards major CYP2C9 substrates and 
therefore may be included in more comprehensive clinical genotyping panels. However, they were not included 
in the Tier 1 recommendations due to either very low multi-ethnic minor allele frequencies (<0.5%) and/or a lack 
of currently available RMs (*13 and *15). As further information is available for these variants and RMs become 
available, they may be promoted to Tier 1 CYP2C9 recommended alleles.   
 
DISCUSSION 
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Professional organizations such as AMP devote resources and efforts to establishing recommendations 
for professional practice, as it is important for molecular diagnostic laboratories to have resources for 
developing and validating clinical diagnostic testing. AMP members are among the early adopters and users of 
PGx testing in clinical settings and have accumulated substantial knowledge and expertise that is useful for 
laboratories beginning to implement these tests. This document offers a two-tier categorization of 
recommended CYP2C9 alleles for inclusion in clinical CYP2C9 genotyping assays. 
The AMP PGx Working Group has proposed a recommended minimum set of alleles and their defining 
variants (Tier 1) that should be included in clinical CYP2C9 genotyping tests based on allele function, population 
frequency, and the availability of RMs. In addition, the Working Group has defined selected CYP2C9 alleles that 
do not currently meet one or more of the criteria for inclusion in Tier 1 and are thus considered optional for 
clinical testing (Tier 2). These recommendations are intended to facilitate standardization of testing by 
laboratories and to improve genotyping concordance across laboratories.    
The Tier 1 alleles recommended for clinical testing were selected based on their reported clinical 
relevance for CYP2C9-associated medications, their frequency, and the availability of RMs.  Tier 1 alleles include: 
CYP2C9*2, *3, *5, *6, *8 and *11. CYP2C9*2 and *3 are the most common alleles in Caucasians and Asians 
(Table 3) and have been extensively investigated among CYP2C9-metabolized medications with narrow 
therapeutic ranges such as warfarin and phenytoin.  Similar data exist for the *5, *6, *8, and *11 alleles, which 
occur predominately in populations of African descent.   
There are currently two published CPIC practice guidelines that involve CYP2C9, and both also incorporate 
additional pharmacogene(s): warfarin (CYP2C9, VKORC1, CYP4F2, and rs12777823)
15
 and phenytoin (CYP2C9 and 
HLA-B).
33
 A CPIC practice guideline for CYP2C9 and celecoxib is in progress (personal communication, K. Caudle). 
A second PGx expert group led by the Royal Dutch Association for the Advancement of Pharmacy, the Dutch 
pharmacogenetics work group (DPWG), offers additional guidance for use of CYP2C9 genotyping for prescribing 
acenocoumarol (not FDA-approved), glibenclamide, gliclazide, glimepiride, phenoprocoumon (not FDA 
approved), and tolbutamide.
34
 Moreover, FDA approved labeling information also includes dosing 
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recommendations based on CYP2C9 genotype for the following medications: celecoxib 
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020998s048lbl.pdf, last accessed 8/15/2018), 
flibanserin (https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf, last accessed 
8/15/2018), flurbiprofen (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018766s020lbl.pdf, last 
accessed 8/15/2018), lesinurad (https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf, 
last accessed 8/15/2018), phenytoin 
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/084349s081s082s084lbl.pdf, last accessed 
8/15/2018), siponimod (https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf, last 
accessed 4/2/2019) and warfarin 
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s118lbl.pdf, last accessed 8/15/2018). As 
such, CYP2C9 testing has the potential to guide clinicians when considering the use of at least 12 different 
medications, some of which are among the top 200 most prescribed medications in the US 
(http://clincalc.com/DrugStats/, last accessed 8/15/2018). 
Although this document provides allele recommendations for all clinical CYP2C9 genotyping indications, 
CYP2C9 testing is closely associated with warfarin dosing. The CYP2C9 enzyme metabolizes the more potent S-
warfarin enantiomer, and the CYP2C9 *2, *3, *5, *6, *8, and *11 alleles are associated with reduced S-warfarin 
clearance.23,31,32,35–37 Data consistently demonstrate reduced warfarin dose requirements in individuals that carry 
these variant alleles, and a recent clinical trial showed that warfarin dosing guided by CYP2C9, VKORC1, and 
CYP4F2 genotypes reduced the composite endpoint of venous thromboembolism, major bleeding, 
supratherapeutic anticoagulation, and death compared to a non-genotype guided approach.
38
  The FDA-
approved warfarin labeling includes dosing recommendations based on CYP2C9 and VKORC1 genotype.
15
 
However, the prescribing information does not include the alleles that have been shown to be important for 
warfarin response in patients of African descent. This is especially relevant for ethnically diverse and admixed 
populations. African alleles may be present in individuals that may not consider themselves of African descent; 
thus, determination of African ethnicity may not be required to test for these alleles. When these alleles are 
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present in any patient regardless of known African descent, they would be associated with reduced metabolism 
and could be used for therapeutic decisions. Failing to account for the CYP2C9*5, *6, *8, and *11 alleles in 
warfarin PGx dosing algorithms may lead to increased risk for over-dosing in African Americans.
15,39,40
  In 
addition, current CPIC guidelines for warfarin dosing underscore the importance of accounting for African alleles 
and provide separate recommendations for patients of African versus non-African ancestry.
15
 As such, we 
recommend that laboratories include all Tier 1 alleles, including the major African alleles, in clinical CYP2C9 
testing.  
The CYP2C9 enzyme is also involved in the metabolism of phenytoin. Patients with a reduced or no 
function allele (eg, *2, *3, *5, *6, *8, *11) are more likely to have impaired metabolism of phenytoin and require 
lower doses of the drug to prevent neurologic toxicity.
30,33,41
 CPIC guidelines recommend consideration of lower 
phenytoin doses in patients who carry reduced function CYP2C9 alleles.
33
  
The Tier 2 recommended CYP2C9 alleles are additional variant alleles that laboratories may choose to 
include in expanded clinical genotyping assays. The three Tier 2 CYP2C9 alleles have been shown to have 
reduced or no function. However, CYP2C9*13 and *15 lack available RMs, and all three alleles have very low 
minor allele frequencies (<0.3%) in major ethnic groups as described above. In particular, the CYP2C9*15 no 
function allele has been found in East Asian (Exome Aggregation Consortium, http://exac.broadinstitute.org/, 
last accessed 8/9/2018) and South Asian populations
22,42
 at very low frequencies (<0.01%), however, testing of 
this allele may more accurately assign phenotype for these ethnic groups.    
The AMP PGx Working Group considered additional CYP2C9 star (*) alleles for possible inclusion in Tier 
2, including CYP2C9*4, *7, *9, *10, *14, *18, *25, *31, and *35. These were not included in Tier 2 at this time 
for the following reasons: YP2C9*4, *10, and *31 are extremely rare and have no appreciable allele frequency 
in multiethnic populations.  CYP2C9*7, *10, and *14 are of uncertain function currently, and therefore are not 
recommended for inclusion in clinical testing panels, although it may be useful to include these alleles in 
research studies designed to measure their phenotypic effect.  CYP2C9*9 is a normal function allele most 
frequent in African populations, with a minor allele frequency of up to 7.5% (Exome Aggregation Consortium, 
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http://exac.broadinstitute.org/, last accessed 8/9/2018); however, since this allele has no effect on enzymatic 
activity, it was not included in recommended clinical test panels as failure to detect it would have no clinical 
significance.  CYP2C9*18 is a recently described variant of unknown allele frequency that shares the *3 allele 
variants, with the addition of a NM_000771.3:c.1425A>T alteration resulting in a p.Asp397Ala amino acid 
change, and is likely a sub-allele of CYP2C9*3.  Similarly, CYP2C9*35 shares  the CYP2C9*2 variant as well as 
having NM_000771.3:c.374G>T (p.Arg125Leu).
19
 More information is necessary regarding the functional 
significance and allele frequency of both CYP2C9*18 and CYP2C9*35 before they could be recommended by the 
Working group for inclusion in clinical genotyping panels.  Although CYP2C9*25 is a frameshift deletion of 10 
nucleotides resulting in loss of function, currently there is no allele frequency information available and it is 
likely to be extremely rare. In addition, for many of these alleles (CYP2C9*4, *7, *14, *25, and *31) there are 
currently no publicly available RMs. 
The AMP PGx Working Group identified seven commercially available platforms for CYP2C9 genotyping 
at the time of this publication.  All of these platforms include *2 and *3; however, only two include all 
recommended Tier 1 alleles, including the African alleles *5, *6, *8, and *11, as well as the Tier 2 alleles (note 
open, platforms such as OpenArray from ThermoFisherh (Waltham MA) may be customized to include all Tier 1 
and Tier 2 alleles). The PGx Working Group is aware that the recommendations to include the alleles more 
prevalent among African and African-American populations may be difficult to implement with currently 
available genotyping platforms.  However, the Working Group concluded that failure to include these alleles 
could lead to inaccurate CYP2C9 phenotype prediction among individuals with known or unknown African 
ancestry and may contribute to existing health care disparities in these populations. Implementation of this 
recommendation document is at the discretion of the laboratory. The Tier 1 alleles are currently included in the 
available proficiency testing (PT) programs [eg, College of American Pathologists 
(http://www.cap.org/web/home/lab/proficiency-testing?_adf.ctrl-
state=8oixhrwfk_4&_afrLoop=116815371771304#, last accessed 8/15/2018), and the North American 
Specialized Coagulation Laboratory Association (https://www.nascola.com/AccessibleServices/Testing, last 
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accessed 8/15/2018)]. The majority of laboratories participating in these PT programs currently test for all of the 
Tier 1 alleles (CAP Biochemical Molecular Genetics Committee, PGX A, 2017 and PGXB, 2017 PT Surveys, College 
of American Pathologists, 2017). This indicates that many clinical laboratories are already testing the Tier 1 
alleles and that these recommendations would be practical to implement and reinforce standardization 
between laboratories.  Of note, FDA has recently approved a direct-to-consumer pharmacogenetics test which 
includes most of the CYP2C9 Tier 1 alleles 
(https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180028.pdf, accessed 11/5/2018), but does not 
include CYP2C9 *8 and *11, which together are found in approximately 8% of individuals with African ancestry 
(https://www.pharmgkb.org/page/cyp2c9RefMaterials, accessed 11/5/2018). 
This AMP document is limited to recommendations for clinical laboratory testing. It does not include, for 
example, mapping of genotypes to phenotype (metabolizer status), clinical interpretation of CYP2C9 genotyping, 
or recommendations for changes to medication therapy based on CYP2C9 genotype. Prediction of CYP2C9 
metabolizer status based on genotype and recommendations for clinical actions based on CYP2C9 phenotype 
are covered by guidelines published by CPIC and other professional groups.  PGx is a rapidly changing field, and 
we intend to update these recommendation documents as new data and/or RMs become available. The AMP 
PGx Working Group recognizes that there are additional alleles that are not listed in this document; there are 
over 60 CYP2C9 alleles currently listed in the PharmVar database (https://www.pharmvar.org/gene/CYP2C9, 
last accessed 8/15/2018). Some of these may be updated to Tier 2 or Tier 1 recommended alleles in the future 
based on new data concerning functional impact, frequency, and availability of RMs.   
In summary, this AMP document provides recommendations for a list of alleles that should be included 
in clinical CYP2C9 genotyping tests. These recommendations are intended to facilitate CYP2C9 genetic testing by 
clinical laboratories.  In addition, these recommendations should help to standardize testing and genotyping 
concordance between laboratories.     
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The Association for Molecular Pathology (AMP) Clinical Practice Guidelines and Reports are developed to be of 
assistance to laboratory and other health care professionals by providing guidance and recommendations for 
particular areas of practice. The Guidelines or Report should not be considered inclusive of all proper 
approaches or methods, or exclusive of others. The Guidelines or Report cannot guarantee any specific 
outcome, nor do they establish a standard of care. The Guidelines or Report are not intended to dictate the 
treatment of a particular patient. Treatment decisions must be made on the basis of the independent judgment 
of health care providers and each patient’s individual circumstances. The AMP makes no warranty, express or 
implied, regarding the Guidelines or Report and specifically excludes any warranties of merchantability and 
fitness for a particular use or purpose. The AMP shall not be liable for direct, indirect, special, incidental, or 
consequential damages related to the use of the information contained herein. 
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Table 1: Commercially Available CYP2C9 Testing Platforms 
CYP2C9 
allele 
Affymetrix 
PharmacoScan 
(RUO)* 
Agena 
Biosciences 
iPLEX ADME 
(RUO)† 
Autogenomics 
INFINITI‡ 
(CE-marked) 
GenMark 
eSensor 
(FDA-
cleared)§  
BioFire 
Defense 
analyte-
specific 
reagents)¶ 
Thermo 
Fisher 
OpenArray 
(V, RUO)* 
TrimGen 
(FDA-
cleared)ǁ 
1B   x       
 
  
1C   x           
1D   x           
2 x x x X X   x 
2C   x           
3 x x x X X   x 
3A   x           
3B   x           
4 x x x         
5 x x x         
6 x x x         
7   x           
8 x x           
9 x x           
10 x x           
11 x   x         
11A   x           
11B   x           
12 x x           
13 x x           
14   x           
15 x x           
16 x x           
17 x x           
18 x x           
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19 x x           
20 x x           
21 x x           
22   x           
23 x x           
24 x x           
25 x x           
26 x x           
27   x           
28   x           
29 x x           
30 x x           
31 x x           
32 x x           
33   x           
34 x x           
36 x             
37 x             
38 x             
39 x             
40 x             
42 x             
43 x             
44 x             
45 x             
46 x             
47 x             
48 x             
49 x             
50 x             
51 x             
52 x             
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53 x             
54 x             
55 x             
56 x             
57 x             
58 x             
Commercially available platforms as of 4/2/2019 and does not represent a comprehensive list. Inclusion herein does not represent an endorsement of 
any product or service by AMP.  
*Thermo Fisher Scientific, (Waltham, MA). 
†Agena Biocience (San Diego, CA). 
‡AutoGenomics (Carlsbad, CA) 
§GenMark Diagnostics (Carlsbad, CA). 
¶BioFire Defense, LLC (Murray, UT). 
ǁTrimGen Genetic Diagnostics (Sparks, MD). 
FDA, Food and Drug Administration; RUO, research use only; V, variable.  
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Table 2. Current Publicly Available Reference Materials for CYP2C9. 
Allele Coriell# (diplotype) 
*2 NA10854 (*2/*2) 
 NA10831 (*1/*2) 
*3 NA10855 [*2/*3 (*18)] 
 NA17290 [*1/*3 (*18)] 
*4 none 
*5 NA23275 (*5/*5) 
 NA19908 (*1/*5) 
 NA19178 (*5/*9) 
*6 NA19213 (*1/*6) 
 NA19143 (*1/*6) 
*7 none 
*8 NA19226 (*1/*8) 
 NA12815 (*1/*8) 
*9 NA07439 (*1/*9) 
 NA19178 (*5/*9) 
*10 NA15245 (*10/*12) 
*11 NA19122 (*1/*11) 
*12 NA15245 (*10/*12) 
*13 none 
*15 none 
*18 NA19917 [*1/*1 (*18)] 
 NA23405 [*1/*3 (*18)] 
This is not a comprehensive list. Inclusion herein does not represent an endorsement of any product or service by AMP. For a complete list, see CDC website. 
(https://wwwn.cdc.gov/clia/Resources/GETRM/default.aspx, last accessed 8/15/2018). 
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Table 3.  CYP2C9 Tier 1 variant alleles. 
Allele Allele Func@onal Status† Defining Functional Variant HGVS Nomenclature: NM_000771.3 
HGVS 
Nomenclature: 
NG_008385.1‡ 
Reference 
Material 
Available 
Multiethnic 
Allele 
Frequency 
*2§ Decreased function rs1799853  c.430C>T, p.Arg144Cys g.8633C>T Yes 0-12% 
*3¶ Decreased function rs1057910  c.1075A>C, p.Ile359Leu g.47639A>C Yes 1-11% 
*5 Decreased function rs28371686 c.1080C>G, p.Asp360Glu g.47644C>G Yes 0-1% 
*6 No function rs9332131 c.818del, p.Lys273Argfs*34 g.15625delA Yes 0-1% 
*8 Decreased function rs7900194 c.449G>A, p.Arg150His g.8652G>A Yes 0-5% 
*11 Decreased function rs28371685 c.1003C>T, p.Arg335Trp g.47567C>T Yes 0-2% 
 
† Citations for assignment of function can be found at https://www.pharmvar.org/gene/CYP2C9, last accessed 8/15/2018.  
‡ CYP2C9 RefSeqGene. 
§ Note that the defining variant of the *35 allele (c.374G>T, p.Arg125Leu) is likely in linkage disequilibrium with the defining *2 variant (c.430C>T, p.Arg144Cys)). 
¶ Note that the defining *18 variant of the allele (c.1190A>C, p.Asp397Ala, rs72558193) is likely in linkage disequilibrium with the defining variant of *3 variant (c.1075A>C, p.Ile359Leu, 
rs1057910). 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  
Table 4.  CYP2C9 Tier 2 variant alleles. 
Allele Allele Func@onal Status† Defining Functional Variant 
HGVS Nomenclature: 
NM_000771.3 
HGVS 
Nomenclature: 
NG_008385.1‡ 
Reference 
Material 
Available 
Multiethnic 
Allele 
Frequency 
*12 Decreased function rs9332239 c.1465C>T, p.Pro489Ser g.55363C>T Yes 0-0.3% 
*13 Decreased function rs72558187 c.269T>C, p.Leu90Pro g.8301T>C No 0-0.2% 
*15 No function rs72558190 c.485C>A, p.Ser162* g.14125C>A No 0-0.01% 
 
† https://www.pharmvar.org/gene/CYP2C9, last accessed 8/15/2018. 
‡ CYP2C9 RefSeqGene; forward relative to chromosome.  
 
 
